PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32664879-9	2020	We further discussed that polymorphisms in ACE2 or TMPRSS2 could guide effective treatments (i.e., hydroxychloroquine and camostat) for COVID-19.	Hydroxychloroquine	99-117	transmembrane serine protease 2	Homo sapiens	51-58	
32793908-5	2020	Chloroquine or hydroxychloroquine increase cleaved active SP-domain of TMPRSS2, and this is potentiated by MEKi.	Hydroxychloroquine	15-33	transmembrane serine protease 2	Homo sapiens	71-78	
33465165-0	2021	Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2.	Hydroxychloroquine	0-18	transmembrane serine protease 2	Homo sapiens	76-83	
33465165-8	2021	We also show that hydroxychloroquine efficiently blocks viral entry mediated by cathepsin L, but not by TMPRSS2, and that a combination of hydroxychloroquine and a clinically-tested TMPRSS2 inhibitor prevents SARS-CoV-2 infection more potently than either drug alone.	Hydroxychloroquine	18-36	transmembrane serine protease 2	Homo sapiens	182-189	
33390974-6	2020	An analysis of the pharmacology of HCQ in COVID-19 reveals certain possible reasons for this failure-a pharmacokinetic failure due to failure to achieve adequate drug concentration at the target site and attenuation of its inhibitory effect due to the presence of TMPRSS2 in airway epithelial cells.	Hydroxychloroquine	35-38	transmembrane serine protease 2	Homo sapiens	264-271	
34826419-0	2022	Hydroxychloroquine treatment on SARS-CoV-2 receptor ACE2, TMPRSS2 and NRP1 expression in human primary pterygium and conjunctival cells.	Hydroxychloroquine	0-18	transmembrane serine protease 2	Homo sapiens	58-65